HIV Treatment Guidelines
Updated Opportunistic Infection Guidelines Add Info on IRIS, Hepatitis, Drug Interactions
- Details
- Category: HIV Treatment Guidelines
- Published on Thursday, 09 May 2013 00:00
- Written by Liz Highleyman
On May 7 the National Institutes of Health, Centers for Disease Control and Prevention, and HIV Medicine Association of the Infectious Diseases Society of Americaannounced the release of revised Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, updating the previous version from 2009.

Updated HIV Treatment Guidelines Include Stronger Recommendation for Acute Infection
- Details
- Category: HIV Treatment
- Published on Friday, 15 February 2013 00:00
- Written by DHHS
On February 12, 2013, the U.S. Department of Health and Human Services antiretroviral therapy (ART) guidelines panel issued an update to the adult and adolescent HIV treatment guidelines. Among the key changes are additional information about the most recently approved antiretroviral agents and a recommendation that newly infected people with HIV should be offered combination ART.

HIV11: New Studies Challenge Evidence of Reduced Abacavir Potency When Viral Load Is High
- Details
- Category: HIV Treatment
- Published on Friday, 30 November 2012 00:00
- Written by Gus Cairns
An analysis of 2 studies of the new HIV integrase inhibitor dolutegravir presented at the 11th International Congress on Drug Therapy in HIV Infection this month in Glasgow had the incidental effect of bringing into question evidence from a previous study suggesting that the nucleoside reverse transcriptase inhibitor abacavir (Ziagen, also in the Epzicom or Kivexa coformulation) was less potent in people starting HIV therapy with high viral loads than another NRTI drug, tenofovir (Viread, also in the Truvada, Atripla, Complera, and Stribild coformulations). 
Liver Toxicity Uncommon with Modern Antiretroviral Drugs, but Higher Risk for HIV/HCV Coinfected
- Details
- Category: HIV Treatment
- Published on Wednesday, 05 December 2012 00:00
- Written by Liz Highleyman
Recently approved antiretroviral drugs are generally well-tolerated and seldom cause serious liver enzyme elevations, although protease inhibitors are somewhat more likely to do so, researchers reported in the November 28, 2012, advance online edition of AIDS. People with HIV/HCV coinfection are more likely to experience liver toxicity, however, and early hepatitis C treatment may improve the tolerability of HIV therapy.
HHS Updates Antiretroviral Treatment Guidelines for Children with HIV
- Details
- Category: HIV Treatment
- Published on Friday, 02 November 2012 00:00
- Written by Liz Highleyman
On November 1, 2012, the U.S. Department of Health and Human Services (HHS) released the latest revision of its Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Key changes include new information on HIV diagnosis of children, when to start treatment, and discussion of newer antiretroviral drugs. 
More Articles...
- New Guidance Addresses Expanded Antiretroviral Treatment, Perinatal ART, PrEP
- New Guidelines: Antiretroviral Therapy and Optimized Care for People with HIV
- CROI: San Francisco Early HIV Treatment Policy Linked to Lower Viral Load, Higher CD4 Count
- DHHS Guidelines Recommend ART for All HIV+, New Info on Older Patients and HIV/HCV Coinfection
Treatment Guidelines















